Clinical trials: Infliximab
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)
This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study.
- Trial name
- REQUEST (NCT00741104)
- Testing
- Infliximab
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Ulcerative Colitis
- Trial name
- NCT04205643
- Testing
- CT-P13 SC (Infliximab)
- Where
- Poland
- Volunteers
- 548 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
RESTART C0168Z05 Rheumatoid Arthritis Study
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition…
- Trial name
- NCT00714493
- Testing
- Infliximab
- Where
- 76 sites in United States, Austria and 8 more
- Volunteers
- 203 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD)
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
- Trial name
- ONWARD (NCT03801928)
- Testing
- Inflectra
- Where
- 15 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Pfizer
Inflammatory Bowel Diseases
Safety of Reduced Infliximab Infusion Time
Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate.
- Trial name
- NCT05340764
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Arthritis, Rheumatoid
A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)
This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852).
- Trial name
- NCT00732875
- Testing
- Infliximab + methotrexate (MTX)
- Volunteers
- 92 people
- Sponsor
- Merck Sharp & Dohme LLC
Inflammatory Bowel Diseases
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
The purpose of this study is to evaluate whether trough serum infliximab concentrations at the time of loss of clinical response will identify pediatric participants with inflammatory bowel disease (IBD) who would benefit (regain…
- Trial name
- ADAPT (NCT02566889)
- Testing
- Infliximab
- Where
- 36 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Janssen Scientific Affairs, LLC
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA.
- Trial name
- NCT00808210
- Testing
- Infliximab, Methotrexate, Methylprednisolone
- Where
- 53 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Kawasaki Disease
Infliximab (Remicade) for Patients With Acute Kawasaki Disease
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.
- Trial name
- NCT00271570
- Testing
- Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Diego
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Crohn's Disease
Treatment With Infliximab in a Medical Setting (Study P05587)
This is an open-label, interventional study where a subset of participants will be randomized to one of two treatment-optimization strategies.
- Trial name
- OPTIMIST (NCT00752622)
- Testing
- Infliximab 5 mg/kg, Infliximab 5 mg/kg every 6 weeks, Infliximab 7 mg/kg every 8 weeks
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)
This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist.
- Trial name
- NCT01313520
- Testing
- Infliximab
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Berylliosis, Beryllium Disease
Beryllium Infliximab Study: Clinical Interventional Trial
The goal of this research study is to test the clinical effectiveness of a drug called infliximab (Remicade) in chronic beryllium disease (CBD).
- Trial name
- BISCIT (NCT00111917)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Maier, Lisa, M.D.
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Kawasaki Disease
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
- Trial name
- NCT00760435
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- University of California, San Diego
Ulcerative Colitis
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.
- Trial name
- NCT00336492
- Testing
- infliximab
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 60 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not…
- Trial name
- NCT02990806
- Testing
- NI-071, Remicade
- Where
- 134 sites in United States, Czechia and 6 more
- Volunteers
- 683 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Crohn's Disease
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
The purpose of this study is to improve the investigators understanding of the relationship between Crohn's disease and blood levels of the drug infliximab (Remicade).
- Trial name
- NCT01438151
- Testing
- Remicade
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shradha Agarwal